A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.

Trial Details

NCT ID

NCT06207123

Phase

PHASE1 / PHASE2

Sponsor

University of Chicago

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

LP-118
Ponatinib
Vincristine
Dexamethasone
Methotrexate

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005
Rochester, New York, United States|43.15478,-77.61556

Key Eligibility Criteria

Relapsed or refractory patients with T-lineage acute lymphoblastic leukemia or T-lymphoblastic lymphoma
18 years old or older
Bone marrow or peripheral blood involvement with ≥5% lymphoblasts or measurable residual disease with \>10-4 level detected by multiparameter flow …
Eastern Cooperative Oncology Group performance status 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →